雖然這篇Neratinib鄉民發文沒有被收入到精華區:在Neratinib這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]Neratinib是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1賀儷安TM 膜衣錠40毫克NERLYNX® (neratinib) tablet 40 mg ...
CONTROL (NCT02400476) 是一項多中心、開放性、多世代(cohort)的試驗,評估以neratinib 每日. 240 mg 治療(為期最多一年)並接受loperamide 預防治療之HER2 陽性早期乳癌 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2臨床藥學大觀園 - 一週全球藥聞
Neratinib (NerlynxR) 為一不可逆激酶抑制劑(kinase inhibitor),藉由阻斷HER2、HER4和EGFR磷酸化及PI3K/AKT和RAS/RAF/MEK/ERK之下游訊息傳遞路徑,進而抑制癌細胞 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3FDA 批准NERLYNX 用於治療轉移性HER2 陽性乳腺癌
Neratinib 為逆激酶抑制劑(kinase inhibitor),可阻斷HER2、HER4、EGFR磷酸化及PI3K / AKT 和RAS / RAF / MEK / ERK 的下游訊息傳遞路徑,達到抑制癌細胞 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Neratinib - Wikipedia
Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5FDA approves neratinib for metastatic HER2-positive breast ...
On February 25, 2020, the Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) in combination with capecitabine for adult ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6Nerlynx 40mg, INN-neratinib - European Medicines Agency ...
Each film-coated tablet contains neratinib maleate, equivalent to 40 mg neratinib. For the full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Neratinib | C30H29ClN6O3 - PubChem
Neratinib is an orally available tyrosine kinase receptor inhibitor that is used in the extended adjuvant therapy of early stage breast cancer. Neratinib is ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Neratinib Approved by FDA for HER2-Positive Breast Cancer
Neratinib (Nerlynx) has been approved by FDA for patients with early-stage HER2-positive breast cancer who have finished at least 1 year of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Phase III NALA Trial - ASCO Journals
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10Neratinib: MedlinePlus Drug Information
Neratinib is used along with capecitabine (Xeloda) to treat a certain type of advanced hormone receptor-positive breast cancer or breast cancer that has spread ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11Nerlynx (neratinib) dosing, indications, interactions, adverse ...
neratinib decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12Neratinib after trastuzumab-based adjuvant therapy in HER2 ...
The international phase 3 Extended Adjuvant Treatment of Breast Cancer with Neratinib (ExteNET) trial was designed to evaluate whether or not 1 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13Neratinib: the emergence of a new player in the management ...
Neratinib is an irreversible pan-HER kinase inhibitor that has emerged as an effective agent when combined with capecitabine for the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Neratinib: Uses, Interactions, Mechanism of Action - DrugBank
Neratinib is a tyrosine kinase inhibitor which exhibits antitumor action against Epidermal Growth Factor Receptor (EGFR), HER2, and Human Epidermal Growth ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15FDA Approves Dose-Escalation Label Amendment for ...
A dose-escalation schedule for neratinib may help some patients with HER2-positive breast cancer better manage severe diarrhea resulting ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16Tyrosine kinase inhibitor neratinib attenuates liver fibrosis by ...
We elucidated the anti-fibrotic effects of neratinib in hepatic stellate cells (HSCs) and in vivo models of CCl4-induced liver fibrosis. HSC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Neratinib - an overview | ScienceDirect Topics
Neratinib is a tyrosine kinase inhibitor used to treat human epidermal growth factor receptor-2 (HER-2) positive breast cancer. The drug binds to and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18Trial of Pre-operative Neratinib and Endocrine Therapy With ...
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Neratinib (HKI-272) | ≥99%(HPLC) | Selleck | HER2 inhibitor
Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Neratinib (HKI-272) | HER2/EGFR Inhibitor | MedChemExpress
Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Neratinib (Nerlynx) for primary breast cancer
Neratinib is a targeted (biological) therapy drug that blocks the growth and spread of breast cancer. Neratinib is the drug's non-branded name. Its brand name ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Neratinib (Nerlynx®) | OncoLink
Neratinib (Nerlynx™) is a kinase inhibitor that works by blocking EGFR and HER kinases.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23Nerlynx 40 mg Film-coated Tablets - eMC
Neratinib may inhibit breast cancer resistance protein (BCRP) at intestinal level as suggested by in vitro studies. A clinical study with BCRP substrates has ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24Neratinib (Nerlynx) - Drug information - Chemocare
Neratinib (Nerlynx) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of breast cancer.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Clinical efficacy and safety of neratinib for breast cancer | DDDT
Neratinib is a 4-anilino-3-cyano quinoline derivative and it is formulated in tablets as neratinib maleate. ... Neratinib irreversibly inhibits ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26Neratinib as extended adjuvant therapy in patients with ...
Neratinib is approved in the European Union for extended adjuvant treatment of human epidermal growth factor receptor 2–positive/hormone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Neratinib (Oral Route) Description and Brand Names - Mayo ...
Neratinib is also used in combination with capecitabine to treat advanced or metastatic HER2-positive breast cancer (breast cancer that has already spread) in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Neratinib in Previously Treated HER2-Positive Metastatic ...
Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Improved tolerability of neratinib in ... - Annals of Oncology
Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Neratinib in the Early-Stage/Extended Adjuvant Breast Cancer ...
Neratinib is a small-molecule tyrosine kinase inhibitor approved for use as a single agent for the extended adjuvant treatment of adult patients with early- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31FDA Approves Dose-Escalation Label Update for Neratinib
The FDA has approved a labeling supplement to the US prescribing information for neratinib that includes the dose-escalated use of the agent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32For healthcare professionals NERLYNX® (neratinib) tablets
NERLYNX is a kinase inhibitor indicated for the treatment of early-stage and metastatic HER2+ breast cancer patients. See recurrence and progression rates ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Neratinib for extended adjuvant treatment of hormone receptor
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Home NERLYNX® (neratinib) tablets
NERLYNX is a prescription medicine used alone to treat adults who have early-stage HER2+ breast cancer. NERLYNX is also used with capecitabine to treat ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Neratinib Uses, Side Effects & Warnings - Drugs.com
What is neratinib? Neratinib is used alone or with other medicines to treat early-stage HER2-positive breast cancer. Neratinib is also used ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36Neoadjuvant neratinib promotes ferroptosis and inhibits brain ...
Neratinib is an irreversible pan-TKI that targets EGFR/HER1, HER2 and HER4. Its potent activity against HER2-overexpressing cells and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37The NEfERT-T Randomized Clinical Trial | Breast Cancer
Question Does neratinib plus paclitaxel improve progression-free survival compared with trastuzumab plus paclitaxel as first-line therapy in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Neratinib - Puma Biotechnology - AdisInsight
In March 2020, neratinib was approved in Switzerland as an extended adjuvant treatment of HER2+ breast cancer . In June 2021, the US FDA approved a labeling ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39Adaptive Randomization of Neratinib in Early Breast Cancer
We used adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibitor neratinib with control. Eligible ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Neratinib tablets - Cleveland Clinic
NERATINIB (ner A ti nib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat breast cancer.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41neratinib (Nerlynx) - Scottish Medicines Consortium
neratinib (Nerlynx®) is accepted for use within NHSScotland. Indication under review: for the extended adjuvant treatment of adult patients ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42Neratinib (Nerlynx®) Diarrhea Management - NCODA
Diarrhea is the main toxicity of neratinib treatment occurring in 95% of patients in the ExteNET trial on the Neratinib arm in which ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43Neratinib Tablet - Uses, Side Effects, and More - WebMD
Find patient medical information for neratinib oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44FDA Approves Dose Escalation Label Update for Puma
Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45Nerlynx (Neratinib): Side Effects, How it Works, and More
Nerlynx (chemical name: neratinib) is a type of targeted therapy called an irreversible pan-HER inhibitor used to treat HER2-positive breast ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Neratinib (Nerlynx) | Cancer information | Cancer Research UK
Neratinib is a targeted cancer drug that works on a protein called human epidermal growth factor receptor 2 (HER2). HER2 proteins make cells ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47Nerlynx (neratinib) | CenterWatch
General Information. Nerlynx (neratinib) is a kinase inhibitor that irreversibly binds to Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Nerlynx (neratinib) for the Treatment of Breast Cancer
Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of early stage HER2-overexpressed or amplified breast cancer in adults.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49neratinib | Michigan Medicine
Neratinib is also used to treat HER2-positive breast cancer that is advanced or has spread to other parts of the body (metastatic). Neratinib is used for breast ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Final Efficacy Results of Neratinib in HER2-positive Hormone ...
Extended adjuvant therapy with neratinib after trastuzumab-based therapy was investigated in the phase III ExteNET trial, in which 1 year of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51Neratinib for breast cancer - Australian Prescriber - NPS ...
Neratinib is indicated for extended adjuvant treatment in women with early-stage HER2-positive breast cancer following adjuvant ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#523656-Breast adjuvant neratinib | eviQ
Concurrent endocrine therapy for hormone receptor-positive patients is standard of care. Drug status: Neratinib is TGA registered but not PBS listed for this ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53PB272 (neratinib) - Puma Biotechnology
We believe neratinib has clinical application in the treatment of several cancers, including breast cancer and gastric cancer. Our initial focus is on the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54A Phase II Study of Neratinib in Patients with Solid Tumors ...
HER2 is a protein which, when abnormal (mutated), can fuel cancer growth. Neratinib is a drug that blocks some of the functions of the HER2 protein. In this ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Neratinib (Nerlynx, Puma Biotechnology, Inc.) with PAP
February 25, 2020-Neratinib (NERLYNX, Puma Biotechnology, Inc.) approved in combination with capecitabine for adult patients with advanced or metastatic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56Oral Adherence With Nerlynx® (Neratinib) Tablets: Introduction
After a one-year course of neratinib 240 mg/day after trastuzumab‑based adjuvant therapy in women with early-stage HER2-positive breast cancer ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57FDA Approves Nerlynx (Neratinib) for a type of Breast Cancer
The US Food and Drug Administration (FDA) has approved the first extended adjuvant therapy for early-stage, HER2-postive breast cancer.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58Abstract OT2-07-09: A phase Ib study of neratinib, pertuzumab ...
The FDA recently approved neratinib as an adjuvant treatment for HER2+ BC patients who have received trastuzumab for at least 1 year.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59Side Effects of Nerlynx (Neratinib Tablets), Warnings, Uses
A comprehensive guide to side effects including common and rare side effects when taking Nerlynx (Neratinib Tablets) includes uses, warnings, and drug ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60Nerlynx (Neratinib) First Extended Adjuvant Therapy ...
Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer · Nerlynx for Extended Adjuvant Treatment · Mechanism of Action.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61Efficacy of Neratinib Plus Capecitabine in the Subgroup of ...
Abstract Background Neratinib has efficacy in central nervous system (CNS) metastases from HER2-positive metastatic breast cancer (MBC).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62Tolerability Improves With Prophylactic Strategies for Adjuvant ...
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63Nerlynx - neratinib - MIMS
Nerlynx(neratinib): Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpresse.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64Efficacy of Neratinib in HER2-Positive, HR-Positive Early ...
The use of neratinib following neoadjuvant/adjuvant trastuzumab-based therapy was associated with improved disease-free survival in this ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65Neratinib for Metastatic HER2 Breast Cancer - NEJM Journal ...
Part 1 of the study established the maximum tolerated dose (MTD) of neratinib plus capecitabine in 33 patients with solid breast cancer tumors ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66product monograph including patient medication information
NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early- stage hormone receptor positive, HER2-overexpressed/ ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67Neratinib (HKI-272) - APExBIO
Neratinib (HKI-272) is a tyrosine kinase inhibitor under investigation for the treatment breast cancer and other solid tumours.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Medline ® Abstract for Reference 20 of 'Adjuvant systemic ...
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69FDA Accepts sNDA for Neratinib Use in HER2-Positive ...
Puma's supplemental New Drug Application is seeking approval for the use neratinib (Nerlynx) plus capecitabine as a third-line treatment in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70FDA approves neratinib regimen for HER2-positive metastatic ...
The FDA approved neratinib as part of combination treatment of HER2-positive metastatic breast cancer, according to the agent's manufacturer ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71[A19-98] Neratinib (breast cancer) - Benefit assessment ...
Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72搜尋條件Puma Biotechnology, Inc. - 台灣藥物臨床試驗資訊網
隨機分配,雙盲,安慰劑控制的試驗。針對罹患HER-2/neu過度表現或基因放大早期乳癌的女性,在使用Trastuzumab後接受Neratinib(HKI-272)治療之 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73Management and Prevention of Neratinib Induced Diarrhea
Intensive loperamide prophylaxis should be used in all patients receiving neratinib for the first cycle of treatment. Key words: Neratinib, diarrhea; ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74NERLYNX (nératinib) - Haute Autorité de Santé
Place de NERLYNX (nératinib) dans la stratégie thérapeutique : Dans ce contexte de traitement adjuvant prolongé et considérant : l'absence de ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Neratinib | Sigma-Aldrich
Find neratinib and related products for scientific research at Merck. ... 抱歉,当前类目未搜索到匹配结果,请点击左边页签查看其他类目下的搜索结果: neratinib ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76Neratinib extends adjuvant treatment of patients with HER2 ...
The small-molecule tyrosine kinase inhibitor neratinib is now approved for the extended adjuvant treatment of patients with early-stage HER2 [human ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Nerlynx: Side effects, dosage, uses, and more - Medical News ...
Nerlynx (neratinib) is a prescription tablet used to treat certain types of breast cancer in adults. Learn about side effects, warnings, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Neratinib | CAS 698387-09-6 | Cayman Chemical | Biomol.com
Neratinib has been evaluated in clinical trials against cancers characterized by HER2 overexpression or HER2 activating mutations. Formal Name: (2E)-N-[4-[[3- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79Mechanism of action of neratinib: an irreversible pan-HER ...
Preliminary data also indicate that neratinib improves patient outcomes in HER2-mutated breast cancer. Conclusions: Therapies to combat ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80Puma Biotechnology Announces Publication of Abstracts on ...
(NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Prior Authorization - Oncology – Nerlynx™ (neratinib tablets)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82neratinib Uses, Side Effects, Dosage & Interactions
Drug Information on neratinib includes side effects, uses, drug interactions, dosage, drug pictures, overdose symptoms, and what to avoid.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Neratinib boosts PFS in pretreated advanced HER2-positive ...
Phase 3 NALA trial supports addition of neratinib to capecitabine in previously treated patients with metastatic HER2-positive breast ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Neratinib - Breast - JNCCN 360
Now, however, an oral anti-HER2 tyrosine kinase inhibitor neratinib (Nerlynx) has been approved for a second year of adjuvant anti-HER2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272 ...
Neratinib has shown promising antitumor activity in a variety of solid tumors, including breast cancer and non-small cell lung cancer (17,18).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Neratinib (HER2抑制剂)(SF5314-25mg) - 碧云天
Neratinib 抑制HER-2,导致下游MAPK和Akt通路受抑制,IC50为2nM,比Trastuzumab更有效。Neratinib作用于BT474细胞,抑制cyclin D1表达和Rb-敏感性基因产物的磷酸化,IC50为 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Buy Nerlynx (neratinib) Online • Price & Costs
Nerlynx (neratinib) is a medication indicated for the adjuvant treatment of adult patients with early-stage HER2 positive overexpressed/amplified breast ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Neratinib for breast cancer – the key is managing ...
Neratinib is an irreversible tyrosine-kinase inhibitor of EGFR (epidermal growth factor receptor), as well as HER1, HER2, and HER4.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Neratinib Nerlynx, Packaging Type: Bottle - IndiaMART
Neratinib is used for this condition only if your tumor tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 protein can ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90Pfizer Announces Neratinib Data In HER2 Positive Breast ...
Neratinib is now part of Pfizer's expanded oncology portfolio, following the recent acquisition of Wyeth. “Data gathered from ongoing clinical trials of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91Neratinib Plus Capecitabine Approved for HER2-Positive ...
The FDA has approved neratinib (Puma Biotechnology), a kinase inhibitor, in combination with capecitabine, for the treatment of adult ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92Neratinib (HKI-272) | HER2 阻害剤 - セレックバイオテック
Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays; weakly inhibits KDR and Src, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93HER2 TKIs for CNS Disease - HER2+ MBC - Module - Clinical ...
Neratinib was originally approved by the FDA as a single agent for extended adjuvant therapy of early HER2-positive breast cancer previously treated with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#94來那替尼(neratinib)的工藝研究 - 每日頭條
來那替尼(neratinib,Nerlynx)是一種口服的、有效的不可逆的酪氨酸激酶抑制劑,像拉帕替尼和阿伐他汀一樣,用於延長輔助治療早期HER2過表達/擴增乳腺癌 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
neratinib 在 コバにゃんチャンネル Youtube 的最佳貼文
neratinib 在 大象中醫 Youtube 的最佳貼文
neratinib 在 大象中醫 Youtube 的最佳解答